IONIS PHARMACEUTICALS INC
CIK 874015 · last filed 2020-10-14
IONIS PHARMACEUTICALS INC is a corporate insider who has filed 13 SEC Form 4 insider transactions across 2 companies since 2012. Across all open-market trades the lifetime net is +$222.5M, making them a net buyer over the disclosed history. The firm reports its address in Carlsbad, CA. 158 SEC filings were submitted jointly with C Frank Bennett.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AKCA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
CARLSBAD, CA 92010
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AKCEA THERAPEUTICS, INC. (AKCA) Delisted | 10%+ Owner | 77,094,682 | — | — | $225.00M | 6 | 2019-12-19 |
| Regulus Therapeutics Inc. (RGLS) Delisted | Director | 45,426 | $8.16 | $370.7K | -$2.50M | 6 | 2015-07-17 |
Recent Filings
13 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-10-14 | — | Buy (P) | +21,237,715 | $385.46M | |
| 2019-12-19 | AKCEA THERAPEUTICS, INC. (AKCA) Delisted | Other (J) | +6,873,344 | $0 | EDGAR |
| 2019-04-02 | AKCEA THERAPEUTICS, INC. (AKCA) Delisted | Other (J) | +2,837,373 | $0 | EDGAR |
| 2018-10-18 | AKCEA THERAPEUTICS, INC. (AKCA) Delisted | Other (J) | +1,671,849 | $0 | EDGAR |
| 2018-08-06 | AKCEA THERAPEUTICS, INC. (AKCA) Delisted | Other (J) | +1,597,571 | $0 | EDGAR |
| 2018-04-19 | AKCEA THERAPEUTICS, INC. (AKCA) Delisted | Mixed | +18,666,666 | $200.00M | EDGAR |
| 2017-07-21 | AKCEA THERAPEUTICS, INC. (AKCA) Delisted | Mixed | +45,447,879 | $25.00M | EDGAR |
| 2015-07-17 | Regulus Therapeutics Inc. (RGLS) Delisted | Sell (S) | −343,133 | -$3.64M | EDGAR |
| 2015-07-02 | Regulus Therapeutics Inc. (RGLS) Delisted | Mixed | — | -$143.0K | EDGAR |
| 2014-10-28 | Regulus Therapeutics Inc. (RGLS) Delisted | Sell (S) | −113,084 | -$1.59M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.